Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer

Publisher： Karger

E-ISSN： 1421-9794|57|2|147-155

ISSN： 0009-3157

Source： Chemotherapy, Vol.57, Iss.2, 2011-03, pp. : 147-155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pemetrexed for Previously Treated Patients with Non-Small Cell Lung Cancer and Differences in Efficacy according to Thymidylate Synthase Expression

By  

Chemotherapy, Vol. 58, Iss. 4, 2012-11 ,pp. : 313-320

Karger

Access to resources Recommend Favorite

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

By Bersanelli Melissa   Buti Sebastiano   Camisa Roberta   Brighenti Matteo   Lazzarelli Silvia   Mazza Giancarlo   Passalacqua Rodolfo  

Cancers, Vol. 6, Iss. 4, 2014-09 ,pp. : 2035-2048

MDPI

Access to resources Recommend Favorite

A Phase II Study of Docetaxel and Infusional Cisplatin in Advanced Non-Small-Cell Lung Cancer

By  

Chemotherapy, Vol. 51, Iss. 2-3, 2005-06 ,pp. : 120-125

Karger

Access to resources Recommend Favorite

A Method for Biomarker Directed Survival Prediction in Advanced Non-Small-Cell Lung Cancer Patients Treated with Carboplatin-Based Therapy

By Chen Wei   Bepler Gerold  

Journal of Personalized Medicine, Vol. 3, Iss. 3, 2013-09 ,pp. : 251-262

MDPI

Access to resources Recommend Favorite

Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents

By  

Chemotherapy, Vol. 62, Iss. 4, 2017-05 ,pp. : 239-245

Karger

Access to resources Recommend Favorite